Patterns and Predictors of Cholinesterase Inhibitor Use in Dementia with Lewy Bodies
Objective: The objective of this study was to identify the patterns and predictors of cholinesterase inhibitor (ChEI) prescribing in Dementia with Lewy bodies (DLB) patients.…Modulation of working memory in prodromal DLB by non-invasive brain stimulation of the striatum and cerebellum
Objective: We aimed to modulate working memory (WM) in patients with MCI with Lewy bodies (MCI-LB) by non-invasive stimulation of the striatum with or without…Carbidopa/levodopa related hypotension in patients with alpha-synucleinopathies
Objective: Evaluate blood pressure response to levodopa/carbidopa in patients with synucleinopathies undergone to autonomic testing. Background: Carbidopa/levodopa is the mainstay treatment of patients with synucleinopathies,…Drug-induced Parkinsonism Mimicking Parkinson´s Disease in Patients Treated with Flunarizine for Migraine
Objective: To understand the pattern of movement disorders caused by migraine prophylactic medicine such as flunarizine. Background: Migraine prophylactic treatments are usually taken for short…Temporal disease patterns prior to Progressive Supranuclear Palsy diagnosis
Objective: To identify Progressive Supranuclear Palsy (PSP) disease trajectories, defined as the pattern of diagnoses over time, prior to PSP diagnosis in electronic health records.…Disease Characteristics of the First 100 Participants in the CurePSP Genetics Program Cohort
Objective: To increase our understanding of the pathogenesis of atypical parkinsonian disorders though genetics, and to build a cohort of individuals for future research. Background:…A rapidly progressive multiple system atrophy-cerebellar variant model presentingα-synuclein oligomer spreading and phosphorylated α-synuclein aggregate formation accompanied with glial inflammation
Objective: We aimed to develop a rapidly progressive mouse model that recapitulates MSA-C pathology. Background: Multiple system atrophy (MSA) is a severe α-synucleinopathy driven by…Multimodal imaging Integrating 18F-APN-1607 and 18F-FP-DTBZ PET in Progressive Supranuclear Palsy
Objective: To identify the regions with sensitive tau deposition for differentiating progressive supranuclear palsy (PSP) from healthy controls. Additionally, to explore the combination of 18F-APN-1607…Expanding the Spectrum of Alzheimer’s Disease Clinical Presentations: Progressive Dysarthria with Monomelic Tremor
Objective: To present an unusual clinical presentation of an atypical Corticobasilar syndrome secondary to Alzheimer's disease. Background: Corticobasilar syndrome (CBS) typically presents with motor symptoms…Utilizing the 15-item modification of the PSPRS rating scale (mPSPRS-15) as the primary endpoint for future clinical trials in progressive supranuclear palsy
Objective: To compare the properties of PSPRS-28, mPSPRS-15, and the rPSPRS-10 and assess their utility as a primary endpoint in PSP trials. Background: Progressive supranuclear…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 181
- Next Page »